Mushroom Strains

Since the introduction of the Psilocybe genus to the western community, various genetic engineering experiences were made birthing various strains, among them the WillSolvem Peyote Strain.

Recent revolutionary research conducted by the Usona Institute unveiled for the first time the true crystal structure of psilocybin opening doors for new psilocybin analogs, such as CYB003, believed to hold the potential to treat major depressive disorder (MDD) and alcohol disorder. This analog is designed to have less variability in the plasma levels, a faster onset of action, shorter duration, and potentially be more tolerable versus oral psilocybin.

Along with the mycological and chemical discoveries, how the substance acts in the brain and its potential use for the treatment of clinical depression is also being explored together with the hypothesis of psilocybe altering the gut microbiome, thus creating a potential avenue for new pharmaceutical tools targeting the gut-brain axis.